Aromatic polyketide compound, and preparation method and application thereof

Abstract

The application discloses an aromatic polyketone compound and a preparation method and application thereof, and belongs to the field of biological medicines. Two aromatic polyketone compounds are produced by streptococcus, and the structural formula is shown as formula (I). The antibacterial activity test is carried out on the compounds 1 and 2, the compounds 1 and 2 have broad-spectrum antibacterial activity on four kinds of gram-positive bacteria, and therefore the aromatic polyketone compounds can provide alternative compounds for developing new antibacterial drugs.

Description

Technical Field

[0001] This invention belongs to the field of biomedicine, specifically relating to an aromatic polyketide compound, its preparation method, and its application. Background Technology

[0002] The information disclosed in this background section is intended only to enhance understanding of the overall background of the invention and is not necessarily to be construed as an admission or in any way implying that such information constitutes prior art known to those skilled in the art.

[0003] Aromatic polyketides represent an important class of natural products derived from a wide variety of sources, including animals, plants, and microorganisms. These compounds exhibit considerable structural diversity and remarkable biological activities. Some aromatic polyketides are used as clinical therapeutic agents; for example, doxorubicin is used in cancer treatment, tetracycline has antibacterial activity, and griseofulvin is used for antifungal applications. Many aromatic polyketides have a naphthalene- or anthracene-based core structure, particularly within a quinone framework. Actinomycetes are considered major producers of naphthoquinone and anthraquinone natural products.

[0004] Therefore, in-depth research into actinomycete secondary metabolites and the development of more new bioactive compounds are problems that need to be solved by those skilled in the art. Summary of the Invention

[0005] To address the shortcomings of existing technologies, the present invention aims to provide an aromatic polyketide compound, its preparation method, and its application. Two aromatic polyketide compounds are produced using streptococci, which can be used to prepare antibacterial drugs.

[0006] To achieve the above objectives, the technical solution of the present invention is as follows:

[0007] In a first aspect, the present invention provides an aromatic polyketide compound, wherein the aromatic polyketide compound is selected from compounds 1 and 2 of the compound shown in formula (I) or their pharmaceutical salts, tautomers or stereoisomers;

[0008] Formula (I).

[0009] Secondly, the present invention provides a method for preparing the above-mentioned aromatic polyketide compounds, comprising the following steps: Actinomycetes Streptomyces sp. SduA 450 was inoculated into the fermentation medium of the strain and fermented. The fermentation product was separated and purified to obtain the aromatic polyketide compound. Actinomycetes Streptomyces sp. SduA 450 is classified as Streptomyces coffee tree. Streptomyces coffeae The actinomycetesStreptomyces sp. The depositary institution for SduA 450 is the China General Microbiological Culture Collection Center (CGMCC), with a deposit date of January 30, 2026. The deposit address is No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, and the accession number is CGMCC No. 37579.

[0010] Thirdly, the present invention provides a composition comprising the above-described aromatic polyketide compound or the aromatic polyketide compound prepared by the above-described preparation method.

[0011] Fourthly, the present invention provides a formulation comprising the above-described aromatic polyketide compound or the aromatic polyketide compound prepared by the above-described preparation method or the above-described composition.

[0012] Fifthly, the present invention provides the use of the above-described aromatic polyketide compounds or the aromatic polyketide compounds obtained by the above-described preparation method or the above-described compositions or preparations in the preparation of antibacterial drugs.

[0013] Furthermore, the antibacterial drug is a drug that inhibits the proliferation of Gram-positive bacteria, including Staphylococcus aureus or its drug-resistant strains, Enterococcus faecalis, and Mycobacterium smegmatis.

[0014] In a sixth aspect, the present invention provides an antibacterial drug comprising the above-described aromatic polyketide compound or the aromatic polyketide compound obtained by the above-described preparation method or the above-described composition or formulation.

[0015] In a seventh aspect, the present invention provides a method for inhibiting Gram-positive bacteria, the method comprising applying the above-mentioned aromatic polyketide compound or the aromatic polyketide compound obtained by the above preparation method or the above-mentioned composition or the above-mentioned preparation or the above-mentioned antibacterial drug to a surface to be inhibited.

[0016] Eighthly, the present invention provides an actinomycete. Streptomyces sp. SduA 450, classified as *Streptomyces coffee treeii*. Streptomyces coffeae The actinomycete is deposited at the China General Microbiological Culture Collection Center (CGMCC) on January 30, 2026, at the Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 37579.

[0017] Ninthly, the present invention provides the above-described actinomycetes. Streptomyces sp. Application of SduA 450 in the preparation of antibacterial drugs.

[0018] One or more of the above technical solutions have the following advantages or beneficial effects: (1) This invention discloses a class of aromatic polyketide compounds 1 and 2 with structures as shown in formula (I), which are derived from actinomycetes. Streptomyces sp.SduA 450 can produce the above-mentioned aromatic polyketide compounds with antibacterial activity, which can be used in the preparation of antibacterial drugs.

[0019] (2) Antibacterial activity tests were conducted on compounds 1 and 2. Gombapyrone M (1) and BE 51068 (2) showed broad-spectrum antibacterial activity against four Gram-positive bacteria. Compound 2 showed more significant activity against Mycobacterium smegmatis. Mycobacterium smegmatis mc 2 155 (MIC = 0.025) µ g / mL), MRSA (MIC = 1) µ g / mL), Enterococcus faecalis Enterococcus faecium 35682 (MIC = 0.025) µ The antibacterial activity of this type of aromatic polyketide compound (g / mL) is stronger than that of the positive control vancomycin, thus providing a potential candidate compound for the development of new antibacterial drugs. This invention provides a new lead compound for the development of novel antibacterial drugs derived from microorganisms. Attached Figure Description

[0020] The accompanying drawings, which form part of this invention, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an improper limitation of the invention.

[0021] Figure 1 The growth morphology and whole genome circle diagram of Streptomyces of the present invention on MS medium are shown; wherein, (a) is a growth morphology diagram and (b) is a whole genome circle diagram; Figure 2 Compound 1 of the present invention 1 H- 1 H COSY and HMBC; Figure 3 High-resolution mass spectra of compound 1 of the present invention; Figure 4 Compound 1 of the present invention 1 H NMR; Figure 5 Compound 1 of the present invention 13 C NMR; Figure 6 Compound 2 of the present invention 1 H NMR; Figure 7 Compound 2 of the present invention 13 C NMR. Detailed Implementation

[0022] In this invention, unless otherwise specified, all other test materials and instruments are conventional test materials in the field and can be purchased through commercial channels.

[0023] strains Streptomyces Sp. Sdu A450 was used for 30 L-scale fermentation. The fermentation products were separated to obtain two aromatic polyketide compounds, namely compound 1 (gombapyrone M) and compound 2 (BE 51068), with chemical structures shown in formula (I).

[0024] The aromatic polyketide compound 1 of this invention is a novel compound that exhibits inhibitory activity against a variety of pathogenic bacteria. Furthermore, compound 2 of the same class has also been found for the first time to show varying degrees of inhibitory activity against multiple pathogenic bacteria. These gomapyrones can be used to prepare antibacterial drugs. Therefore, this invention provides candidate compounds for the development of new antibacterial drugs and is of great significance for the development of microbial drug resources.

[0025] Actinomycetes Streptomyces The 16S rRNA gene sequence of sp. SduA 450 is shown in SEQ ID NO: 1.

[0026]

[0027] In one typical embodiment, the present invention provides an aromatic polyketide compound selected from compounds 1 and 2 of formula (I) or their pharmaceutical salts, tautomers, or stereoisomers: Formula (I).

[0028] In a typical embodiment, the present invention provides a method for preparing the above-mentioned aromatic polyketide compound, comprising the following steps: Actinomycetes Streptomyces sp. SduA 450 was inoculated into the fermentation medium of the strain and fermented. The fermentation product was separated and purified to obtain the aromatic polyketide compound.

[0029] Specifically: Actinomycetes Streptomyces sp. SduA 450 was inoculated into a spore fermentation medium to obtain spores, which were then inoculated into a seed fermentation medium to obtain seeds. These seeds were then inoculated into a bacterial fermentation medium to obtain seeds. The fermentation products were separated and purified to obtain the aromatic polyketide compound.

[0030] Among them, the actinomycetes Streptomyces sp. SduA 450 was identified as a Streptomyces species by 16S rRNA gene sequencing and morphological analysis. This Streptomyces was isolated from the root of the plant Xanthium sibiricum.

[0031] This strain is deposited at the China General Microbiological Culture Collection Center (CGMCC) on January 30, 2026. The deposit address is No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, with accession number CGMCC No. 37579.

[0032] In one or more embodiments, during the process of obtaining spores through fermentation in a spore fermentation medium, the spore fermentation medium is MS medium, which, by mass percentage, comprises: 2-20% soybean flour, 2-20% mannitol, 2-20% agar powder, with the balance being water, and a pH of 7.2-7.4.

[0033] Furthermore, the spore fermentation culture conditions are constant temperature culture at 28~32℃ for 4~6 days.

[0034] In one or more embodiments, during the fermentation culture in the seed culture medium, the seed culture medium is Am2ab medium, which, by mass percentage, contains 4-6 g starch, 18-22 g glucose, 1-3 g yeast extract, 1-3 g bacteriological peptone, 4-6 g soybean flour, 0.3-0.7 g MgSO4•7H2O, 0.3-0.7 g KH2PO4, 2-6 g NaCl, 1-3 g CaCO3, with the balance being water, and a pH of 7.2-7.4. Preferably, the mixture contains 5 g starch, 20 g glucose, 2 g yeast extract, 2 g bacteriological peptone, 5 g soybean flour, 0.5 g MgSO4·7H2O, 0.5 g KH2PO4, 4 g NaCl, 2 g CaCO3, with the balance being water, and a pH of 7.2-7.4.

[0035] Furthermore, the seed fermentation culture conditions are constant temperature culture at 28~32℃ for 1-3 days and 100-300 rpm.

[0036] In one or more embodiments, during the fermentation culture of the strain inoculated into the fermentation medium, the fermentation medium includes Am2ab medium and also includes 1-3% macroporous adsorption resin.

[0037] The fermentation conditions in the fermentation medium for this strain are constant temperature culture at 28~32℃ for 6-8 days and 100-300 rpm.

[0038] In one or more embodiments, the separation and purification includes centrifuging, eluting, and concentrating the fermentation product under reduced pressure to obtain a crude extract; the crude extract is subjected to normal-phase silica gel column chromatography using mobile phase A, the components are collected, and the separation and purification are performed using a chromatographic column to obtain the target product.

[0039] Furthermore, the centrifugation conditions are 3000-4500 rpm for 10-20 min.

[0040] Furthermore, the elution conditions are as follows: elution with alcohol, such as ethanol, sonication for 20-40 minutes, and elution multiple times, such as 2-7 times.

[0041] Preferably, the total crude extract is prepared using mobile phase A (dichloromethane / methanol system, 50-100:0-50). v:vNormal-phase silica gel column chromatography was performed, yielding a total of 10 fractions, denoted as Fr. A1-A10. Fractions Fr. A5-A7 were combined and precipitated on an ODS column using mobile phase B (water / methanol, 10% methanol-100% methanol, 80 min) at a flow rate of 15-25 mL / min, resulting in 7 fractions, denoted as Fr. E1-E7. Fraction Fr. E4 was precipitated on a Sephadex LH-20 column, resulting in 9 fractions, denoted as Fr. F1-F9. Fractions Fr. E6 and E7 were precipitated on a Sephadex LH-20 column, resulting in 8 fractions, denoted as Fr. G1-G8. Fraction Fr. G5 was subjected to semi-preparative HPLC using mobile phase C (45% water-55% acetonitrile) at a flow rate of 1-3 mL / min, yielding compounds 1 and 2.

[0042] In one typical embodiment, the present invention provides a composition comprising the above-described aromatic polyketide compound or the aromatic polyketide compound prepared by the above-described preparation method.

[0043] In one typical embodiment, the present invention provides a formulation comprising the above-described aromatic polyketide compound or the aromatic polyketide compound prepared by the above-described preparation method, or the above-described composition.

[0044] In a typical embodiment, the present invention provides the use of the above-described aromatic polyketide compounds or aromatic polyketide compounds prepared by the above-described preparation method, or the above-described compositions or preparations in the preparation of antibacterial drugs.

[0045] Furthermore, the antibacterial drug is a drug that inhibits the proliferation of Gram-positive bacteria, including Staphylococcus aureus or its drug-resistant strains, Enterococcus faecalis, and Mycobacterium smegmatis.

[0046] The Staphylococcus aureus can be Staphylococcus aureus 29213.

[0047] The drug-resistant strain of Staphylococcus aureus mentioned above can be methicillin-resistant Staphylococcus aureus (MRSA).

[0048] The Enterococcus faecalis can be Enterococcus faecium 35682.

[0049] The smegma mycobacterium can be Mycobacterium smegmatis mc 2 155.

[0050] In one typical embodiment, the present invention provides an antibacterial drug comprising the above-described aromatic polyketide compound or the aromatic polyketide compound prepared by the above-described preparation method, or the above-described composition or formulation. It also includes a pharmaceutically acceptable carrier or excipient.

[0051] In a typical embodiment, the present invention provides a method for inhibiting the proliferation of Gram-positive bacteria, comprising the following steps: applying the above-mentioned aromatic polyketide compound or the aromatic polyketide compound prepared by the above-mentioned preparation method, or the above-mentioned composition or the above-mentioned formulation to the surface to be inhibited.

[0052] In one typical embodiment, the present invention provides an actinomycete. Streptomyces sp. SduA 450, the actinomycete is deposited at the China General Microbiological Culture Collection Center (CGMCC) on January 30, 2026, at the Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 37579.

[0053] In one typical embodiment, the present invention provides the above-mentioned actinomycetes. Streptomyces sp. Application of SduA 450 in the preparation of antibacterial drugs. Specifically, as described in the second aspect above, culturing actinomycetes can yield aromatic polyketide compounds.

[0054] To enable those skilled in the art to better understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below with reference to specific embodiments.

[0055] Example 1: Actinomycetes Streptomyces Cultivation, identification and fermentation of sp. SduA 450 1. Actinomycetes Streptomyces Solid culture of sp. SduA 450: Actinomycetes Streptomyces sp. SduA 450 was stored on MS medium slant. The MS medium consisted of 20 g soybean powder, 20 g mannitol, 20 g agar powder, and water to a final volume of 1 L, with a pH of 7.2-7.4.

[0056] 2. Actinomycetes Streptomyces Identification of the 16S rRNA gene of sp. SduA 450: Actinomycetes were picked from the preservation tubes and transferred to MS plates, then incubated at 28 °C for 4 days. In a clean bench, bacterial cells were then transferred using a bamboo skewer to 250 mL Erlenmeyer flasks containing 50 mL of TSB medium and incubated at 200 rpm and 28 °C for 2 days. The cells were centrifuged at 3900 rpm for 15 min using 50 mL centrifuge tubes, the supernatant was discarded, and the whole genome of the bacteria was sequenced. The obtained sequences were then assembled and analyzed using BLAST. The 16S rRNA gene is shown in SEQ ID NO: 1.

[0057] 3. Actinomycetes Streptomyces Fermentation of sp.SduA 450 Will Streptomyces sp. Sdu A450 was inoculated onto fresh MS agar plates and cultured for 5 days at 28 °C to serve as a seed plate. Then, samples were picked... Streptomyces Spores of *S. sdu* A450 were inoculated into a 250 mL Erlenmeyer flask containing 50 mL of Am2ab medium and cultured at 28 °C and 200 rpm for 2 days as the seed culture medium. The Am2ab medium consisted of: 5 g starch, 20 g glucose, 2 g yeast extract, 2 g bacteriological peptone, 5 g soybean flour, 0.5 g MgSO4·7H2O, 0.5 g KH2PO4, 4 g NaCl, 2 g CaCO3, diluted to 1 L with water, pH 7.2-7.4. Subsequently, 25 mL of the seed culture medium was inoculated into a 1 L Erlenmeyer flask containing 200 mL of Am2ab medium and 2% (w / w) macroporous adsorption resin and cultured at 28 °C and 200 rpm for 7 days. Approximately 30 L of the strain... Streptomyces The sp. Sdu A450 amplified fermentation culture was centrifuged (3900 rpm, 15 min) to separate the bacterial broth and bacterial cells (2% macroporous adsorption resin). The bacterial cells and 2% macroporous adsorption resin were eluted with ethanol, sonicated for 30 min, and eluted a total of 5 times. The crude extract was concentrated under reduced pressure to obtain the crude extract.

[0058] Streptomyces was isolated from the root of the plant Xanthium sibiricum. The growth morphology and whole genome circle of the strain on MS medium are shown below. Figure 1 As shown, the 16S rRNA gene sequence of the strain is shown in SEQ ID NO: 1.

[0059] Example 2: Isolation, purification, and structural identification of gommapyrones-like compounds For the obtained total extract of the crude extract, normal-phase silica gel column chromatography was carried out using a dichloromethane / methanol system (100:0, 99:1, 98:2, 97:3, 96:4, 95:5, 94:6, 92:8, 90:10, 50:50, v / v). The elution volume for each gradient was 2 L, and a total of 10 fractions were obtained, denoted as Fr. A1 - A10. Fractions Fr. A5 - A7 were combined and passed through an ODS column. The mobile phase was water / methanol (10% methanol - 100% methanol, 80 min, with each gradient being 10 minutes), and the flow rate was 20 mL / min, resulting in 7 fractions, denoted as Fr. E1 - E7. Fraction Fr. E4 was subjected to Sephadex LH-20 column chromatography and separated into 9 fractions, denoted as Fr. F1 - F9; fractions Fr. E6E7 were subjected to Sephadex LH-20 column chromatography and separated into 8 fractions, denoted as Fr. G1 - G8. Fraction Fr. G5 was semi-prepared by HPLC with elution conditions of 45% water - 55% acetonitrile and a flow rate of 2 mL / min to obtain compound 2 ( t R = 53.4 min, m = 10.3 mg), 1 ( t R = 56.4 min, m = 7.3 mg).

[0060] Through HRESIMS and nuclear magnetic resonance analysis, compound 1 is a new compound. Compound 1 is a yellow oily solid, soluble in dichloromethane and methanol. The HRESIMS cation shows its quasi-molecular ion peak [M H] m / z 389.2117 (calcd for 389.2111), and the deduced molecular formula is C 26 H 30 O3, and its calculated unsaturation is 12.

[0061] Compound 2 is a known compound, a yellow oily solid, soluble in dichloromethane and methanol. The low-resolution mass spectrum shows its [M H] m / z to be 405.6. Combining with 13 C NMR, its molecular formula is determined to be C 26 H 30 [[ID=3,2]]O4, and the unsaturation is 12. Combining with 1 H NMR and 13 C NMR information, by comparison, it is determined to be the known compound BE 51068.

[0062] Table 1. Nuclear magnetic resonance of compound 1 1 H and13 C-spectral data (600 MHz, TMS as internal standard, ppm)

[0063] Example 3: Antibacterial activity of the compound The effects of compounds 1 and 2 on each other were determined using the two-fold dilution method. Staphylococcus aureus 29213、 Mycobacterium smegmatis mc 2 155, MRSA , Enterococcus faecium The test procedure for the antibacterial activity of 35682 is briefly described below: (1) The pathogens to be tested were activated in LB broth medium, the rotation speed was set to 200 rpm, and the culture was carried out at 37°C until the concentration reached an optical density (OD) value of about 1.0. (2) Accurately weigh the sample to be tested and the appropriate positive control. Dissolve all samples in dimethyl sulfoxide (DMSO) to prepare a series of 2-fold serially diluted compound solutions with a concentration range of 3.2 to 0.625 mg / mL in DMSO; (3) Pour an appropriate amount of sterile LB broth medium into a sterile plate. Dilute the cultured pathogen to be tested with the appropriate medium until the optical density (OD) value is 1.0, and then further dilute it 1000 times; (4) Add 100 to the first column, the first row, and the last left row of the 96-well plate. µ L of sterile LB broth was used as a negative control, while the other columns were prepared with 99 g of sterile LB broth. µ L is the corresponding diluted pathogen to be tested; (5) Take 1 µ The test sample L and the positive control drug were added sequentially to a 96-well plate. The drug concentrations in columns 2 to 11 were 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, and 0.0625, respectively. µ The concentration is displayed in g / mL, while column 12 is the positive control for the corresponding drug. Carefully blow the solution up and down several times into the wells containing the sample and positive control to ensure thorough mixing. (6) Place the 96-well plate that has undergone the above operations in an incubator at 37 ℃ and keep it in a static state for incubation; the incubation time is set to 12 to 24 hours (due to the different growth rates of different pathogens, the specific incubation time needs to be determined according to the actual situation of the strain to be tested). (7) Record the specific value of the minimum inhibitory concentration (MIC) for each sample; (8) Three parallel experiments should be set up for each sample.

[0064] The inhibitory activities of compounds 1 and 2 against the four pathogenic bacteria are shown in Table 2.

[0065] Table 2. Inhibitory activities of compounds 1 and 2 against four pathogenic bacteria.

[0066] The antibacterial activity of these two aromatic polyketide compounds was evaluated. Antibacterial activity tests showed that compound 2 was effective against Mycobacterium smegma. Mycobacterium smegmatis mc 2 155, MRSA, Enterococcus faecium Enterococcus faecium The activity of 35682 was stronger than that of the positive control vancomycin, with MIC values ​​of 0.025, 1, and 0.025, respectively. µ g / mL. Compound 1 also exhibits strong antibacterial activity against four types of Gram-positive bacteria.

[0067] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. An aromatic polyketide compound, characterized in that, The aromatic polyketide compound is selected from compounds 1 and 2 of formula (I) or their pharmaceutical salts, tautomers or stereoisomers. Formula (I).

2. A method for preparing the aromatic polyketide compound according to claim 1, characterized in that, Includes the following steps: Actinomycetes Streptomyces sp. SduA 450 was inoculated into the fermentation medium of the strain and fermented. The fermentation product was separated and purified to obtain the aromatic polyketide compound. The actinomycetes Streptomyces sp. The depositary institution for SduA 450 is the China General Microbiological Culture Collection Center (CGMCC), with a deposit date of January 30, 2026. The deposit address is No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, and the accession number is CGMCC No. 37579.

3. A composition, characterized in that, This includes the aromatic polyketide compound of claim 1 or the aromatic polyketide compound prepared by the preparation method of claim 2.

4. A formulation, characterized in that, Includes the aromatic polyketide compound of claim 1, the aromatic polyketide compound prepared by the preparation method of claim 2, or the composition of claim 3.

5. The use of an aromatic polyketide compound of claim 1, an aromatic polyketide compound obtained by the preparation method of claim 2, a composition of claim 3, or an formulation of claim 4 in the preparation of an antibacterial drug.

6. The application according to claim 5, characterized in that, The antibacterial drug is a drug that inhibits the proliferation of Gram-positive bacteria, including Staphylococcus aureus or its drug-resistant strains, Enterococcus faecalis, and Mycobacterium smegmatis.

7. An antibacterial drug, characterized in that, It comprises the aromatic polyketide compound of claim 1, the aromatic polyketide compound obtained by the preparation method of claim 2, the composition of claim 3, or the formulation of claim 4.

8. A method for in vitro inhibition of Gram-positive bacteria, the method not for the purpose of diagnosing or treating a disease, the method comprising applying to a surface to be inhibited an aromatic polyketide compound of claim 1, an aromatic polyketide compound obtained by the preparation method of claim 2, a composition of claim 3, an formulation of claim 4, or an antibacterial drug of claim 7.

9. An actinomycete Streptomyces sp. SduA 450, characterized in that, The actinomycete is deposited at the China General Microbiological Culture Collection Center (CGMCC) on January 30, 2026, at the Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 37579.

10. The actinomycete according to claim 9 Streptomyces sp. Application of SduA 450 in the preparation of antibacterial drugs.

Images